OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Gradishar Reviews Findings From the LEA Trial

January 17th 2013

William J. Gradishar, MD, from the Northwestern University Feinberg School of Medicine, reviews results from the phase III LEA trial that investigated add-on bevacizumab in breast cancer.

Dr. Smita Bhatia on Anthracycline-Related CHF

January 17th 2013

Smita Bhatia, MD, MPH, Population Sciences, City of Hope, Duarte, California, explains a clinical trial analyzing genetic susceptibility to anthracycline-related congestive heart failure in survivors of hematopoietic cell transplantation.

Dr. Fanale on Frontline Brentuximab in Lymphoma

January 16th 2013

Michelle A. Fanale, MD, from the MD Anderson Cancer Center, discusses a phase I trial that examined the frontline administration of brentuximab vedotin for patients with subtypes of lymphoma.

Dr. Sara Tolaney on Cabozantinib in Breast Cancer

January 16th 2013

Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute and Brigham and Women's Hospital, discusses trials investigating cabozantinib in breast cancer.

Dr. Brian Durie on Novel Therapies in Multiple Myeloma

January 15th 2013

Brian G. M. Durie, MD, Cedars-Sinai Medical Center, Senior Advisor, Hematologic Malignancies, National Program Director, Multiple Myeloma and Related Disorders for Aptium Oncology, discusses novel therapies for multiple myeloma.

Dr. Schuster on Detecting Bone Metastases in Breast Cancer

January 15th 2013

David Schuster, MD, director, from Emory University, compares the efficacy of bone scans and FDG-PET/CT scans for detecting bone metastases in patients with breast cancer.

Dr. Corey Langer Discusses Erlotinib in Advanced NSCLC

January 15th 2013

Corey J. Langer, MD, from the University of Pennsylvania, Abramson Cancer Center, discusses the EGFR-targeted tyrosine kinase inhibitor erlotinib for patients with non-small cell lung cancer.

Dr. Zelenetz on the Impact of Rituximab in Lymphoma

January 14th 2013

Andrew D. Zelenetz, MD, PhD, from the Memorial Sloan-Kettering Cancer Center, explains the impact that rituximab has made in the treatment of patients with non-Hodgkin and B-cell lymphomas.

Dr. Holcombe Discusses Aflibercept for mCRC

January 14th 2013

Randall F. Holcombe, MD, Tisch Cancer Institute at Mount Sinai Medical Center, speaks about the use of aflibercept in patients with metastatic colorectal cancer.

Dr. Debu Tripathy on the CDK4/6 Inhibitor PD 0332991

January 11th 2013

Debu Tripathy, MD, from the USC Norris Comprehensive Cancer Center, discusses a phase II trial that examined the CDK inhibitor PD 0332991 for women with advanced estrogen receptor-positive breast cancer.

Dr. Matthew Katz on Borderline Resectable Pancreatic Cancer

January 11th 2013

Matthew H.G. Katz, MD, from the MD Anderson Cancer Center, discusses borderline resectable pancreatic ductal adenocarcinoma, a newer stage of pancreatic cancer introduced by the NCCN in 2003.

Dr. Sridhar on Nab-Paclitaxel in Urothelial Cancer

January 10th 2013

Srikala Sridhar, MD, MSc, from the University of Toronto, Canada, discusses the results of a single arm phase II trial examining nab-paclitaxel as a secondary treatment for urothelial cancer.

Dr. Dizon on PTEN Mutations in Endometrial Cancer

January 10th 2013

Don S. Dizon, MD, Assistant in Medicine, Medical Gynecologic Oncology, Massachusetts General Hospital, explains the relationship between PTEN mutations and mTOR inhibitors in endometrial cancer.

Dr. Cervantes Discusses COMFORT-II Long-Term Data

January 10th 2013

Francisco Cervantes, MD, PhD, Hospital Clinic, IDIBAPS, Barcelona, Spain, discusses the initial and long-term findings of the COMFORT-II trial of ruxolitib for the treatment of myelofibrosis.

Dr. Perez on the Phase III Eribulin/Capecitabine Study

January 9th 2013

Edith A. Perez, MD, from the Mayo Clinic Cancer Center, Florida, discusses the results of a phase III study comparing the efficacy of eribulin mesylate to capecitabine in patients with locally advanced or metastatic breast cancer.

Dr. Mark Kris on Performance Status in Lung Cancer

January 9th 2013

Mark G. Kris, MD, chief of the Thoracic Oncology Service at Memorial Sloan-Kettering Cancer Center, discusses the importance of accurately determining a patient's performance status.

Dr. Oh on Combination Therapy in Prostate Cancer

January 8th 2013

William K. Oh, MD, from the Tisch Cancer Institute at Mount Sinai Medical Center, discusses ongoing research into combination strategies for men with castration-resistant prostate cancer.

Dr. Gettinger on Lung Cancer Immunotherapies

January 8th 2013

Scott Gettinger, MD, associate professor of medicine (medical oncology), Yale School of Medicine, explains the development of immunotherapies in lung cancer.

Dr. Posner on HPV-Positive Oropharynx Cancer

January 7th 2013

Marshall Posner, MD, from Mount Sinai Medical Center, discusses the factors that improve the prognosis for patients with HPV-positive head and neck cancer when compared to patients who are HPV-negative.

Dr. Gradishar Discusses 10 Years of Adjuvant Tamoxifen

January 4th 2013

William J. Gradishar, MD, from the Northwestern University Feinberg School of Medicine, discusses results from the international ATLAS study that was presented at the 2012 San Antonio Breast Cancer Symposium.